It is interesting to note that if, on the one hand, the introduction of phosphorylation sites can be evolutionarily beneficial, as in the case of brain aromatase, on the other hand, phosphorylation of residues that increases aromatase activity can strengthen the negative effects of estrogens, as in the case of breast cancer. Here, CYP19A1 is linked to breast carcinoma.